IP Library Granted Patent US 11,427,613
Granted Patent B2
US 11,427,613 · App. 16/492,766 · Granted Aug 30, 2022

Method for purification of albumin

Inventors: Jin Seog Seo (Mississauga, CA); David Miller (Guelph, CA)
Assignee: Evolve Biologics Inc.
C07K1/34C07K14/765
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,427,613
App. No.
16/492,766
Granted
Aug 30, 2022
Kind
B2
Abstract

A method for the purification of albumin from plasma is described. The method comprises (a) contacting the plasma with sodium caprylate (NaCP) at an amount dependent on total protein concentration and the ratio of NaCP to total protein in the plasma, (b) heating the plasma at a near neutral pH range, and (c) separating the albumin from non-albumin-phase. The said method provides for a high yield and purity albumin solution.

Claims (25)

1. A method for purifying albumin from plasma comprising:

(a) contacting the plasma with sodium caprylate (NaCP),

wherein the amount of NaCP is between 0.8 and 1.3 mmol NaCP per gram of total protein in the plasma;

(b) heating the plasma at a temperature between 60 and 70° C.;

(c) separating the albumin from the non-albumin phase; and

(d) recovering at least 75% of albumin from plasma;

wherein the total protein in the plasma in (a) is in a concentration between 50 and 80 g/L.

2. A method according to claim 1 , wherein the plasma is partially purified plasma, cryo poor plasma, plasma intermediate, solution of plasma proteins, or mixtures thereof.

3. A method according to claim 1 , wherein the heating of the plasma is carried out at a pH between 6.0 and 8.0, optionally between 6.5 and 7.5, optionally between 6.7 and 7.3, optionally between 6.7 and 6.9.

4. A method according to claim 1 , wherein conductivity of the plasma during heating is less than 9 mS/cm, optionally less than 5 mS/cm.

5. A method according to claim 1 , wherein the heating of the plasma is carried out at a temperature between 60 and 70° C., optionally between 62 and 65° C., for a period between 0.5 and 24 hours, optionally between 2 and 12 hours, optionally between 3 and 12 hours, optionally between 4 and 6.5 hours.

6. A method according to claim 1 , wherein the heating of the plasma is carried out at a pH between 6.7 and 6.9 at a temperature between 62 and 65° C. for a period of at least 4 hours, wherein the amount of NaCP is between 0.8 and 1.3 mmol NaCP per gram of total protein, wherein the total protein is in a concentration between 50 and 80 g/L.

7. A method according to claim 1 , wherein the concentration of total protein is adjusted by the addition of water.

8. A method according to claim 1 , wherein the separation of the albumin from the non-albumin phase comprises precipitation of non-albumin protein and lipid impurities.

9. A method according to claim 1 , wherein the separation of the albumin from the non-albumin phase comprises cooling the plasma to below 30° C.

10. A method according to claim 1 , wherein the separation of the albumin from the non-albumin phase comprises filtering through depth filtration, tangential flow filtration (TFF) with a cassette or hollow fibre TFF.

11. A method according to claim 1 , wherein the separation of the albumin from the non-albumin phase comprises adjusting the pH of the plasma to between 4.8 and 5.4, optionally between 5.1 and 5.3.

12. A method according to claim 11 , wherein the adjustment of the pH of the plasma is carried out by the addition of acid.

13. A method according to claim 12 , wherein the acid comprises an organic and/or inorganic acid.

14. A method according to claim 13 , wherein the organic acid is selected from citric acid, acetic acid and trifluoroacetic acid.

15. A method according to claim 13 , wherein the organic acid is acetic acid.

16. A method according to claim 13 , wherein the inorganic acid is selected from hydrochloric acid, sulfuric acid and phosphoric acid.

17. A method according to claim 10 , wherein the separation of albumin from non-albumin comprises filtration at feed flow between 1 and 10 L/min per m 2 , optionally between 2 and 10 L/min per m 2 , optionally between 3 and 10 L/min per m 2 , optionally between 8 and 9 L/min per m 2 .

18. A method according to claim 1 , wherein the method can be linearly scalable.

19. The method according to claim 10 , wherein the separation of the albumin from the non-albumin phase comprises filtering through hollow fibre TFF.

Assignments (5)
SECURITY INTEREST Recorded May 31, 2023
From: EVOLVE BIOLOGICS INC.; TBI PHARMA HOLDINGS LTD.
To: MONROE CAPITAL MANAGEMENT ADVISORS, LLC
Reel/Frame 063817/0151 →
RELEASE OF SECURITY INTEREST Recorded Oct 21, 2020
From: MIDCAP FINANCIAL TRUST
To: EVOLVE BIOLOGICS INC.
Reel/Frame 054123/0957 →
CONFIRMATORY INTELLECTUAL PROPERTY ASSIGNMENT Recorded Oct 23, 2019
From: THERAPURE BIOPHARMA, INC.
To: EVOLVE BIOLOGICS INC.
Reel/Frame 050798/0522 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 22, 2019
From: THERAPURE BIOPHARMA INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050797/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2019
From: SEO, JIN SEOG; MILLER, DAVID
To: THERAPURE BIOPHARMA INC.
Reel/Frame 050327/0328 →
Continuity (2)
Provisional Application 62472007 · Mar 16, 2017
Related Publication 20210139534A1 · May 13, 2021